TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Cipla Ltd.
CIPLALarge CapNSEBSE
Healthcare · Healthcare
₹1,415.30down 4.70down 0.33 percentas of 28 Aug 2026
Book value ₹423.74Div yield 0.92%
Key metrics
- Market Cap
- 1,14,492.99 ₹ cr
- P/E
- 29.66 x
- P/B
- 3.34 x
- ROE
- 28.14%
- ROCE
- 34.39%
- Debt to Equity
- 0.33 x
- Net Margin
- 14.05%
- Dividend Yield
- 0.92%
- Revenue Growth (YoY)
- 2.33%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 29.2% (pledge data not available).
- Debt-to-equity 0.33 — above the Healthcare median of 0.31.
CIPLA
₹1,415.30down 0.33 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatModerate Return
12.51%ROCE
ROE: 11.27%·P/B: 3.34x
2. Forensic Health & SolvencyPiotroski 4/9 · Adequate Health
4/9Piotroski Score
Altman: 10.2 (Safe Zone)
3. Valuation & DCF Spread-88.0% Valuation Premium
₹170DCF Fair Value
CMP: ₹1,415.3
4. Ownership & GovernanceClean Promoter Holding
29.21%Promoter Stake
Pledged: 0.0%·Inst: 40.76%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #12 of 46 in HealthcareQVGM 56/100
Quality (Q)79
ROE, ROCE, Margins & Cash Conversion
Value (V)57
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)39
3Y Sales & EPS Compounded Growth
Momentum (M)43
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #12 of 46 in Healthcare
Valuation
Moderate57/100
P/E Ratio:29.66x
P/B Ratio:3.34x
Dividend Yield:0.92%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Weak39/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Strong79/100
ROE:11.3%
ROCE:12.5%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate44/100
Piotroski F-Score:4/9
Altman Z-Score:10.22
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Moderate43/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹1,192.40
From 52W High-14.93%
52-Week High₹1,663.60
Valuation MultiplesCash Flow & Yield
PEG Ratio2.64
Earnings Yield26.85%
Price / FCF81.71
FCF Yield1.22%
Payout Ratio3.42%
Net-Net Ratio-18.35
Solvency & SafetyPiotroski & Altman
Piotroski F-Score4/9
Altman Z-Score10.22
Graham Number₹1,903.28
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▼ 2.35%
DII Stake:▲ +1.90%
OPM Margin:▼ 6.59%
Net Margin:▼ 5.37%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +8.84% | ▲ +2.33% | 2.23% | 7.37% | 8.01% |
| Net Profit Growth | ▲ +42.26% | ▼ 39.19% | -26.43% | 11.45% | 10.03% |
| EPS Growth | ▲ +34.25% | ▼ 39.23% | -21.06% | 11.25% | 11.14% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — CIPLA
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹173.5
Verdict:Overvalued (-87.7%)
Benjamin Graham Number
₹702.5
-50.4% vs CMPPeter Lynch Fair Value
₹257.3
-81.8% vs CMPReverse DCF Implied Growth
60.0% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹1,415.3
₹0 (Distress)CMP: ₹1,415DCF: ₹174Graham: ₹703
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR6.0%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 6% | ₹912 | 0.8969 | ₹818 |
| Year 2 | 6% | ₹967 | 0.8044 | ₹778 |
| Year 3 | 6% | ₹1,025 | 0.7214 | ₹740 |
| Year 4 | 6% | ₹1,087 | 0.6470 | ₹703 |
| Year 5 | 6% | ₹1,152 | 0.5803 | ₹668 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹182 -87% | ₹205 -85% | ₹220 -84% | ₹238 -83% | ₹286 -80% |
| 11.0% | ₹160 -89% | ₹176 -88% | ₹187 -87% | ₹199 -86% | ₹230 -84% |
| 11.5% | ₹150 -89% | ₹165 -88% | ₹174 -88% | ₹184 -87% | ₹209 -85% |
| 12.0% | ₹142 -90% | ₹155 -89% | ₹162 -89% | ₹171 -88% | ₹192 -86% |
| 13.0% | ₹128 -91% | ₹138 -90% | ₹143 -90% | ₹150 -89% | ₹165 -88% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E29.66current
ReportedComputed, approximate
P/B3.34current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 29.66 | 3.34 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Buy(2.30 / 5)
Strong Buy:8
Buy:15
Hold:10
Sell:3
Strong Sell:1
Coverage: 37 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Moderate risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:22.76%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +7.61%
Mean Target₹1,523.00vs CMP ₹1,415.30
High Target₹1,820.00+28.6% max upside
Low Target₹1,120.00-20.9% downside
Median Target₹1,550.0037 estimates
Low: ₹1,120.00Mean: ₹1,523.00High: ₹1,820.00
Mean Target Current Price (₹1,415.30)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹11.62
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹12.34
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹14.00
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹15.48
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹14.57
Low:—
High:—
FY2025E5 Analysts
Mean Estimate
₹16.12
Low:—
High:—
FY2025E5 Analysts
Mean Estimate
₹19.43
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹15.12
Low:—
High:—
FY2026E5 Analysts
Mean Estimate
₹16.06
Low:—
High:—
FY2026E6 Analysts
Mean Estimate
₹16.72
Low:—
High:—
FY2026E8 Analysts
Mean Estimate
₹8.36
Low:—
High:—
FY2026E9 Analysts
Mean Estimate
₹6.86
Low:—
High:—
FY2027E7 Analysts
Mean Estimate
₹9.76
Low:—
High:—
FY2027E4 Analysts
Mean Estimate
₹11.41
Low:₹10.00
High:₹12.00
FY2027E4 Analysts
Mean Estimate
₹14.11
Low:₹12.00
High:₹14.00
FY2027E4 Analysts
Mean Estimate
₹13.46
Low:₹10.00
High:₹15.00
FY2028E1 Analysts
Mean Estimate
₹13.73
Low:₹13.00
High:₹13.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹11.62 | — | — | — |
| FY2024 Forecast | ₹12.34 | — | — | — |
| FY2024 Forecast | ₹14.00 | — | — | — |
| FY2024 Forecast | ₹15.48 | — | — | — |
| FY2025 Forecast | ₹14.57 | — | — | — |
| FY2025 Forecast | ₹16.12 | — | — | 5 |
| FY2025 Forecast | ₹19.43 | — | — | 5 |
| FY2025 Forecast | ₹15.12 | — | — | 6 |
| FY2026 Forecast | ₹16.06 | — | — | 5 |
| FY2026 Forecast | ₹16.72 | — | — | 6 |
| FY2026 Forecast | ₹8.36 | — | — | 8 |
| FY2026 Forecast | ₹6.86 | — | — | 9 |
| FY2027 Forecast | ₹9.76 | — | — | 7 |
| FY2027 Forecast | ₹11.41 | ₹12.00 | ₹10.00 | 4 |
| FY2027 Forecast | ₹14.11 | ₹14.00 | ₹12.00 | 4 |
| FY2027 Forecast | ₹13.46 | ₹15.00 | ₹10.00 | 4 |
| FY2028 Forecast | ₹13.73 | ₹13.00 | ₹13.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
3 Factors- •Company is virtually debt-free with a Debt-to-Equity ratio of 0.02x.
- •Strong cash generation: Operating Cash Flow is 101.6% of reported Net Profit.
- •High institutional backing: FIIs & DIIs hold a combined 40.8%.
Risk Factors & Watchouts
0 WatchoutsClean profile: No major debt, leverage, or working capital red flags detected.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score4 / 9
● Moderate (Neutral)
Altman Z-Score10.22
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.15
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
22.2%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
3.1%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
78.2%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹3,879 CrInflow
3,879
+ D&A Non-Cash Charge₹1,083 CrAdd-back
1,083
Working Capital Adjustment-₹1,022 Cr- Tied Up
1,022
= Operating Cash Flow (CFO)₹3,940 CrOperating Cash
3,940
- Capital Expenditures (CapEx)-₹3,079 CrReinvestment
3,079
= Free Cash Flow (FCF)₹861 CrFree Cash Flow
861
- Dividends & Debt Repayment-₹853 CrCapital Return
853
= Net Change in Cash₹8 CrNet Balance
8
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2014-201531 Mar 2015 | 2015-201631 Mar 2016 | 2016-201731 Mar 2017 | 2017-201831 Mar 2018 | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | ₹16,362.41 | ₹17,131.99 | ₹19,159.59 | ₹21,763.34 | ₹22,753.12 | ₹25,774.09 | ₹27,547.62 | ₹28,162.59 |
| Operating profit | — | — | — | — | ₹1,777.12 | ₹2,040.80 | ₹3,199.54 | ₹3,332.74 | ₹3,706.09 | ₹5,059.11 | ₹6,156.59 | ₹4,438.52 |
| OPM | — | — | — | — | 10.86% | 11.91% | 16.70% | 15.31% | 16.29% | 19.63% | 22.35% | 15.76% |
| Net profit | — | — | — | — | ₹1,527.70 | ₹1,546.52 | ₹2,404.87 | ₹2,516.75 | ₹2,801.91 | ₹4,121.55 | ₹5,272.52 | ₹3,879.23 |
| EPS | — | — | — | — | 20.97 | 19.80 | 30.35 | 33.28 | 37.37 | 53.76 | 65.19 | 51.46 |
| Net margin | — | — | — | — | 9.34% | 9.03% | 12.55% | 11.56% | 12.31% | 15.99% | 19.14% | 13.77% |
| ROE | — | — | — | — | 10.18% | 9.81% | 13.12% | 12.08% | 11.97% | 15.43% | 16.90% | 11.27% |
| ROCE | 15.00% | 13.00% | 7.00% | 9.00% | 8.80% | 10.59% | 15.56% | 15.02% | 15.22% | 18.42% | 19.30% | 12.51% |
| Debt / equity | — | — | — | — | 0.29 | 0.20 | 0.11 | 0.05 | 0.03 | 0.02 | 0.01 | 0.02 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Revenue | 2.23% | 7.37% | 8.01% | — |
| Net profit | -26.43% | 11.45% | 10.03% | — |
| EPS | -21.06% | 11.25% | 11.14% | — |
Each column only appears when 12 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | ₹23,963.32 | ₹23,662.56 | ₹25,151.89 | ₹27,101.12 | ₹29,463.28 | ₹32,717.82 | ₹37,387.04 | ₹42,495.98 |
| Total liabilities | — | — | — | — | ₹8,951.04 | ₹7,899.56 | ₹6,825.36 | ₹6,259.43 | ₹6,055.50 | ₹6,011.39 | ₹6,193.59 | ₹8,064.03 |
| Total equity | — | — | — | — | ₹15,012.28 | ₹15,763.00 | ₹18,326.53 | ₹20,841.69 | ₹23,407.78 | ₹26,706.43 | ₹31,193.45 | ₹34,431.95 |
| Total debt | — | — | — | — | ₹4,316.23 | ₹3,089.20 | ₹2,014.41 | ₹1,055.78 | ₹803.12 | ₹559.41 | ₹438.19 | ₹613.77 |
| Cash | — | — | — | — | ₹481.01 | ₹553.06 | ₹643.54 | ₹612.35 | ₹543.90 | ₹613.64 | ₹577.02 | ₹945.28 |
| Current assets | — | — | — | — | ₹12,426.63 | ₹11,706.18 | ₹13,209.51 | ₹14,727.54 | ₹17,274.95 | ₹19,441.41 | ₹23,288.52 | ₹24,145.86 |
| Current liabilities | — | — | — | — | ₹3,771.51 | ₹4,393.14 | ₹4,591.55 | ₹4,913.21 | ₹5,109.67 | ₹5,245.77 | ₹5,483.96 | ₹7,013.59 |
| Inventory | — | — | — | — | ₹4,175.02 | ₹4,569.37 | ₹4,839.52 | ₹5,542.96 | ₹5,367.89 | ₹5,449.75 | ₹5,846.01 | ₹6,782.23 |
| Receivables | — | — | — | — | ₹4,150.72 | ₹3,891.31 | ₹3,445.68 | ₹3,448.05 | ₹4,100.36 | ₹4,813.92 | ₹5,543.66 | ₹5,662.11 |
| Payables | — | — | — | — | ₹1,947.99 | ₹2,281.81 | ₹2,066.82 | ₹2,508.10 | ₹2,457.05 | ₹2,473.98 | ₹2,837.49 | ₹3,229.90 |
| Net PP&E | — | — | — | — | ₹5,445.40 | ₹5,549.05 | ₹5,527.11 | ₹5,547.30 | ₹5,679.95 | ₹5,933.29 | ₹6,475.02 | ₹7,626.08 |
| Retained earnings | — | — | — | — | ₹13,297.70 | ₹14,166.41 | ₹16,557.76 | ₹18,690.81 | ₹21,096.73 | ₹24,406.08 | ₹28,639.16 | ₹31,159.28 |
Cash flow
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | ₹1,691.14 | ₹3,068.45 | ₹3,755.20 | ₹3,325.90 | ₹3,237.65 | ₹4,133.91 | ₹5,004.98 | ₹3,940.02 |
| Capital expenditure | — | — | — | — | ₹-527.14 | ₹-1,000.01 | ₹-818.92 | ₹-701.15 | ₹-1,182.89 | ₹-1,349.30 | ₹-1,548.20 | ₹-3,079.31 |
| Free cash flow | — | — | — | — | ₹1,164.00 | ₹2,068.44 | ₹2,936.28 | ₹2,624.75 | ₹2,054.76 | ₹2,784.61 | ₹3,456.78 | ₹860.71 |
| OCF / net profit | — | — | — | — | 1.11 | 1.98 | 1.56 | 1.32 | 1.16 | 1.00 | 0.95 | 1.02 |
| FCF / Capex intensity | — | — | — | — | 3.22 | 5.84 | 4.27 | 3.22 | 5.20 | 5.24 | 5.62 | 10.93 |
Income statement detail
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | — | — | — | — | ₹9,666.30 | ₹10,195.18 | ₹10,830.95 | ₹12,202.59 | ₹13,438.88 | ₹15,816.87 | ₹17,387.70 | ₹17,293.71 |
| Cost of revenue | — | — | — | — | ₹6,696.11 | ₹6,936.81 | ₹8,328.64 | ₹9,560.75 | ₹9,314.24 | ₹9,957.22 | ₹10,159.92 | ₹10,868.88 |
| EBITDA | — | — | — | — | ₹2,872.78 | ₹3,138.11 | ₹4,200.11 | ₹4,320.57 | ₹4,723.92 | ₹5,998.21 | ₹7,149.97 | ₹5,521.12 |
| Income before tax | — | — | — | — | ₹2,079.14 | ₹2,178.18 | ₹3,290.06 | ₹3,493.27 | ₹4,038.35 | ₹5,701.90 | ₹6,820.81 | ₹5,223.63 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax expense | — | — | — | — | ₹569.53 | ₹631.20 | ₹888.76 | ₹933.80 | ₹1,202.86 | ₹1,546.59 | ₹1,529.76 | ₹1,353.84 |
| D&A | — | — | — | — | ₹1,095.66 | ₹1,097.31 | ₹1,000.57 | ₹987.83 | ₹1,017.83 | ₹939.10 | ₹993.38 | ₹1,082.60 |
| EBITDA margin | — | — | — | — | 17.56% | 18.32% | 21.92% | 19.85% | 20.76% | 23.27% | 25.95% | 19.60% |
Financial ratios
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | — | — | — | — | 3.29 | 2.66 | 2.88 | 3.00 | 3.38 | 3.71 | 4.25 | 3.44 |
| Quick ratio | — | — | — | — | 2.19 | 1.62 | 1.82 | 1.87 | 2.33 | 2.67 | 3.18 | 2.48 |
| Interest coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory days | 329.00 | 273.00 | 239.00 | 271.00 | 227.58 | 240.43 | 212.09 | 211.61 | 210.35 | 199.77 | 210.02 | 227.76 |
| Receivable days | 64.00 | 62.00 | 65.00 | 75.00 | 92.59 | 82.91 | 65.64 | 57.83 | 65.78 | 68.17 | 73.45 | 73.38 |
| Payable days | 126.00 | 106.00 | 108.00 | 142.00 | 106.18 | 120.06 | 90.58 | 95.75 | 96.29 | 90.69 | 101.94 | 108.47 |
| Cash conversion cycle | 267.00 | 230.00 | 196.00 | 204.00 | 213.98 | 203.27 | 187.15 | 173.69 | 179.85 | 177.25 | 181.53 | 192.68 |
| Working capital days | 89.00 | -10.00 | 99.00 | 118.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Fixed asset turnover | — | — | — | — | 3.00 | 3.09 | 3.47 | 3.92 | 4.01 | 4.34 | 4.25 | 3.69 |
| ROA | — | — | — | — | 6.38% | 6.54% | 9.56% | 9.29% | 9.51% | 12.60% | 14.10% | 9.13% |
| ROIC | — | — | — | — | 6.85% | 7.92% | 11.86% | 11.47% | 11.00% | 13.83% | 15.38% | 9.64% |
| Gross margin | — | — | — | — | 59.08% | 59.51% | 56.53% | 56.07% | 59.06% | 61.37% | 63.12% | 61.41% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
13.77%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.66
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.23
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
11.27%
Reported: 11.27%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 05 Jun 2026 | dividend | 650% |
| 2025 | 27 Jun 2025 | dividend | 150% |
| 27 Jun 2025 | dividend | 650% | |
| 2024 | 02 Aug 2024 | dividend | 650% |
| 2023 | 21 Jul 2023 | dividend | 425% |
| 2022 | 10 Aug 2022 | dividend | 250% |
| 2021 | 11 Aug 2021 | dividend | 250% |
| 2020 | 20 Mar 2020 | dividend | 50% |
| 20 Mar 2020 | dividend | 150% | |
| 2019 | 02 Aug 2019 | dividend | 150% |
| 02 Aug 2019 | dividend | 150% | |
| 2018 | 16 Aug 2018 | dividend | 150% |
| 2017 | 28 Jul 2017 | dividend | 100% |
| 2016 | 15 Sept 2016 | dividend | 100% |
| 2015 | 13 Aug 2015 | dividend | 100% |
| 2014 | 08 Aug 2014 | dividend | 100% |
| 2013 | 08 Aug 2013 | dividend | 100% |
| 2012 | 03 Aug 2012 | dividend | 100% |
| 2011 | 11 Aug 2011 | dividend | 100% |
| 2010 | 06 Sept 2010 | dividend | 40% |
| 27 Jul 2010 | dividend | 100% | |
| 2009 | 12 Aug 2009 | dividend | 100% |
| 2008 | 14 Aug 2008 | dividend | 100% |
| 2007 | 10 Aug 2007 | dividend | 100% |
| 2006 | 22 Aug 2006 | dividend | 100% |
| 25 Apr 2006 | bonus | 3:2 |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 7 dividend distributions
Latest Year DPS:₹13.00
Yield on CMP:0.92%
3Y Dividend CAGR:+15.2%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹60.50
₹13.0
2026
₹16.0
2025
₹13.0
2024
₹8.5
2023
₹5.0
2022
₹5.0
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 05 Jun 2026 | ₹13.00 | Final |
| 27 Jun 2025 | ₹13.00 | Final |
| 27 Jun 2025 | ₹3.00 | Special |
| 02 Aug 2024 | ₹13.00 | Final |
| 21 Jul 2023 | ₹8.50 | Final |
| 08 Aug 2022 | ₹5.00 | Final |
| 09 Aug 2021 | ₹5.00 | Final |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap1,14,492.99 ₹ cr
Beats 94% of 65 industry peers · median 21,553.63 ₹ cr
P/E29.66 x
Beats 18% of 60 industry peers · median 51.05 x
P/B3.34 x
Beats 15% of 62 industry peers · median 6.18 x
ROE28.14%
Beats 89% of 65 industry peers · median 14.13%
ROCE34.39%
Beats 92% of 65 industry peers · median 16.38%
Debt to Equity0.33 x
Beats 52% of 65 industry peers · median 0.31 x
Net Margin14.05%
Beats 62% of 65 industry peers · median 13.15%
Dividend Yield0.92%
Beats 79% of 53 industry peers · median 0.42%
Revenue Growth (YoY)2.33%
Beats 13% of 64 industry peers · median 19.32%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Laurus Labs Ltd.LAURUSLABS | ₹1.05 L | 117.32 | 19.65 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Cipla Ltd. (CIPLA)
Indexed Documents8 Filings
Latest Disclosure18 Jul 2026
Investor Deck18 Jul 2026
Cipla Ltd: Investor Presentation on Q4 Financial Results and Growth Outlook
Concall Transcript07 Jul 2026
Cipla Ltd: Transcript of Earnings Conference Call with Institutional Investors
Shareholding06 Jun 2026
Cipla Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
Press Release12 May 2026
Cipla Ltd: Press Release: Business Updates and New Strategic Initiatives
Secretarial Filing30 Apr 2026
Cipla Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Board Outcome02 Apr 2026
Cipla Ltd: Outcome of Board Meeting for Approval of Audited Financial Results
AGM / EGM27 Feb 2026
Cipla Ltd: Notice of Annual General Meeting and Record Date for Dividend
News
- IndianAPIBombay HC pulls up Maharashtra FDA over enforcement actions: What businesses need to know
The Bombay High Court has scrutinised Maharashtra FDA's enforcement actions against businesses, including Cipla, restaurants, hotels and dairies, questioning due process and proportionality while allowing relief in several cases.
- IndianAPIBuy or sell: Ganesh Dongre of Anand Rathi recommends 3 stocks to buy on Monday - 31 August 2026
Indian stock market: Amid ongoing Middle East Tension, Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday. Check top stock picks by the market expert.
- IndianAPITukaram Mundhe-led Maharashtra FDA cancels Cipla unit's drug licence over Reactin Plus irregularities
FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an analgesic and antipyretic.
- IndianAPIRaja Venkatraman recommends three stocks for 26 August
Market expert Raja Venkatraman shares his top stock picks for 26 August. Here’s his technical outlook and trade strategy.
- IndianAPISensex gains 287 points, Nifty 50 ends at 24,335- What drove the stock market up today?
The Sensex closed 287 points, or 0.37%, higher at 77,656, while the Nifty settled at 24,335, rising 116 points, or 0.48%.
- IndianAPIWhy has the Centre barred certain cold medicines for children under four?
The regulatory action follows safety recommendations from an expert committee and the Drugs Technical Advisory Board.
- IndianAPIStock market today: Gift Nifty hints a flat start; eight day trading stocks to buy on Wednesday, 19 August
Indian stock markets are anticipated to open flat amidst weak global cues, following a steep decline in the previous session. Brent crude prices rose amid supply concerns, while global financial markets remain risk-averse due to the US-Iran standoff and its impact on energy supplies.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPIStocks to watch: LIC, Trent, Ola Electric among shares in focus today; check list here
Stock market today: Gift Nifty was trading near the 24,666 mark, up over 18.3 points from the previous close of Nifty futures.
- IndianAPIStocks to watch: LIC, Trent, Ola Electric among shares in focus today; check list here
Stock market today: Gift Nifty was trading near the 24,666 mark, up over 18.3 points from the previous close of Nifty futures.
- IndianAPIRaja Venkatraman recommends three stocks for 4 August
Market expert Raja Venkatraman shares his top stock picks for 4 August. Here’s his technical outlook and trade strategy.
- IndianAPIRaja Venkatraman recommends three stocks for 4 August
Market expert Raja Venkatraman shares his top stock picks for 4 August. Here’s his technical outlook and trade strategy.
- IndianAPIProfit squeeze clouds strong June-quarter revenue growth for India Inc
Higher commodity prices and healthy demand lifted revenues. But rising costs kept margins under pressure, with financial companies emerging as the biggest support for Q1FY27 earnings so far.
- IndianAPIProfit squeeze clouds strong June-quarter revenue growth for India Inc
Higher commodity prices and healthy demand lifted revenues. But rising costs kept margins under pressure, with financial companies emerging as the biggest support for Q1FY27 earnings so far.
- IndianAPIStock recommendations for 27 July from MarketSmith India
MarketSmith India reveals its top stock recommendations for today, 27 July. Get expert insights into the best-performing stocks to guide your investment decisions.
- IndianAPIStock recommendations for 27 July from MarketSmith India
MarketSmith India reveals its top stock recommendations for today, 27 July. Get expert insights into the best-performing stocks to guide your investment decisions.
- IndianAPIMint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?
From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins.
- IndianAPIMint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?
From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins.
- IndianAPIRaja Venkatraman recommends three stocks for 24 July
Market expert Raja Venkatraman shares his top stock picks for 24 July. Here’s his technical outlook and trade strategy.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.